How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,755 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1721. Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease (PubMed)

Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease Granzyme B (GrB) and T-cell-restricted intracellular antigen (TIA-1) are cytotoxic proteins that are specifically expressed by cytotoxic CD4 or CD8 positive T cells and natural killer cells. Recent studies demonstrated frequent expression of GrB and TIA-1 by neoplastic cells in primary cutaneous CD30(+) large T-cell lymphomas and lymphomatoid papulosis (...) but not in CD30(-) large T-cell lymphomas. In the present study, 74 biopsies from 54 patients with mycosis fungoides (MF) were investigated for the expression of GrB and TIA-1 using immunohistochemistry on paraffin sections. Staining of more than 10% of the neoplastic T cells for GrB or TIA-1 was considered positive. All but two follow-up biopsies had been obtained from patients without extracutaneous disease at the time of biopsy. Expression of TIA-1 and GrB was found in 33 (45%) and 14 (19%) of 74 MF

Full Text available with Trip Pro

1999 The American journal of pathology

1722. Cutaneous expression of Thy-1 in mycosis fungoides. (PubMed)

Cutaneous expression of Thy-1 in mycosis fungoides. Dermal dendritic cells from eleven cases of mycosis fungoides (MF) (six patch and five plaque stage), two cases of pre-MF, and five specimens of normal human skin, were characterized immunohistochemically using a panel of antibodies including anti-human Thy-1, intercellular adhesion molecule-1 (ICAM-1; CD54), endothelial leukocyte adhesion molecule-1 (ELAM-1), vascular cell adhesion molecule-1 (VCAM-1), CD1a, CD2, CD14, CD18, CD34, MAC387, KP

Full Text available with Trip Pro

1992 The American journal of pathology

1723. Ocular involvement in mycosis fungoides. (PubMed)

Ocular involvement in mycosis fungoides. A case of mycosis fungoides with bilateral intraocular involvement is reported. The diagnosis was established with the aid of a vitreous biopsy. Intraocular involvement, though rare, may be an early sign of extracutaneous disease.

Full Text available with Trip Pro

1993 The British journal of ophthalmology

1724. Hodgkin's disease following mycosis fungoides: phenotypic and molecular evidence for different tumour cell clones. (PubMed)

Hodgkin's disease following mycosis fungoides: phenotypic and molecular evidence for different tumour cell clones. (1) To assess the clonality of tumour cells in two patients with mycosis fungoides who subsequently developed Hodgkin's disease; and (2) to determine whether there is a clonal relation between these two disorders.Cutaneous tissue samples involved by mycosis fungoides and lymph nodes involved by Hodgkin's disease from both patients were investigated by immunohistochemistry (...) and the polymerase chain reaction.Mycosis fungoides tumour cells in both patients expressed multiple T cell associated antigens; Reed-Sternberg (RS) cells had the null phenotype. T cell receptor gamma chain genes were clonally rearranged in mycosis fungoides cells but not in RS cells, including variants, in both patients. In the patient with intermediate transformation to large cell lymphoma, immunoglobulin heavy chain genes were rearranged in the cutaneous tumour, but not in the lymph node involved by Hodgkin's

Full Text available with Trip Pro

1996 Journal of Clinical Pathology

1725. Interleukin-2 in Treating Patients With Mycosis Fungoides

Interleukin-2 in Treating Patients With Mycosis Fungoides Interleukin-2 in Treating Patients With Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Interleukin-2 in Treating Patients (...) With Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00002687 Recruitment Status : Completed First Posted : January 27, 2003 Last Update Posted : December 4, 2012 Sponsor: University of Washington Information provided by (Responsible Party): University of Washington Study Details Study

1999 Clinical Trials

1726. Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides

Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00002557 Recruitment Status : Unknown Verified August 2000 by National Cancer Institute (NCI). Recruitment status was: Active, not recruiting First Posted : July 19

1999 Clinical Trials

1727. Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00005788 Recruitment Status : Terminated (Low/inadequate rate of accrual.) First Posted : January 27, 2003 Last Update Posted : June 6, 2012 Sponsor: Northwestern University

2000 Clinical Trials

1728. Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tretinoin (...) in Treating Patients With Mycosis Fungoides or Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00002479 Recruitment Status : Completed First Posted : August 23, 2004 Last Update Posted : May 30, 2012 Sponsor: Northwestern University Collaborator: National Cancer Institute (NCI) Information

1999 Clinical Trials

1729. Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00047060 Recruitment Status : Completed First Posted : January 27, 2003 Last Update Posted

2002 Clinical Trials

1730. Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00004106 Recruitment Status : Terminated (Per Data Monitoring Committee given the poor/inadequate accrual.) First Posted : January 27, 2003 Last Update Posted : June 6, 2012 Sponsor

1999 Clinical Trials

1731. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. (PubMed)

Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. Oral retinoids seem to have been of great benefit in a non-randomized study on advanced mycosis fungoides using two different chemotherapy regimens, one with retinoid, the other without. Both groups also received a 3-drug chemotherapy with bleomycin, cyclophosphamide and prednisone. Complete remission including all signs of lymph-node involvement was found in 8 of 10 patients (...) of the retinoid treated group, while none went into complete remission in the control group. All in the control group died between 3 and 12 months after therapy, whereas all but one in the retinoid treated group are alive. Other treatment differences between the groups were related to the use of transfer factor, topical treatment, and steroid administration. These differences make a final evaluation of the use of retinoids in mycosis fungoides difficult at the present stage. Further studies are needed.

1982 Acta dermato-venereologica

1732. Intralesional interferon in the treatment of early mycosis fungoides. (PubMed)

Intralesional interferon in the treatment of early mycosis fungoides. Twelve patients with early mycosis fungoides were enrolled in a randomized, double-blind, placebo-controlled study. Isolated plaques were injected three times a week with recombinant alpha 2-interferon in nine patients and with the vehicle in three patients. Two additional plaques were evaluated in each patient; one was left untreated, and another was treated topically with either placebo ointment or betamethasone ointment

1985 Journal of the American Academy of Dermatology

1733. Transfer factor therapy in mycosis fungoides: a double-blind study. (PubMed)

Transfer factor therapy in mycosis fungoides: a double-blind study. Sixteen patients with mycosis fungoides (MF) were given either active transfer factor (TF) or heat-inactivated TF as additional therapy to topical nitrogen mustard or PUVA. The TF was prepared from non-selected healthy blood donors. The clinical evaluation after 2 years of therapy showed that among 8 patients treated with active TF, none went into complete remission of their disease 4 patients had partial remission, one (...) levels of T lymphocytes in peripheral blood. A temporary increase was observed in the total number of T lymphocytes in patients after one month of treatment with active TF. After one year the T lymphopenia had disappeared in both groups. The mitogen reactivity of lymphocytes was found to be normal (PHA, PWM) or somewhat reduced (Con A). It is concluded that under the conditions employed in this trial, TF was not able to prevent progression of early mycosis fungoides, when viewed over a period of 2

1982 Acta dermato-venereologica

1734. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. (PubMed)

Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. A two-part clinical trial was conducted to determine the therapeutic efficacy of recombinant interferon alfa-2b in plaque-phase mycosis fungoides. In an initial randomized double-blind study, each of six patients had two representative plaques injected intralesionally with 1 X 10(6) U of recombinant interferon alfa-2b per site and two control plaques injected with placebo three

1987 Archives of Dermatology

1735. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. (PubMed)

Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Radiotherapy has been successfully implemented in the treatment of mycosis fungoides (MF) for almost a century. With the development of the modern linear accelerator, it has become possible to treat extended areas of the skin with accelerated electrons. Total skin electron beam radiation (TSEB) has been in use

2002 Journal of American Academy of Dermatology

1736. Treatment of childhood mycosis fungoides with topical PUVA. (PubMed)

Treatment of childhood mycosis fungoides with topical PUVA. Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, which is usually observed in mid to late adulthood. We report 5 cases of mycosis fungoides in children, all presenting as patch- and plaque-stage disease most commonly involving the buttocks. Histologic examination showed in every case the typical features of mycosis fungoides. In 4 of the 5 cases, the infiltrating lymphocytes were characterized by the T-cell (...) phenotype CD3(+), CD4(+), CD8(+); and in 3 cases, a monoclonal rearrangement of the T-cell receptor gamma (TCR-gamma) gene was found. Three children received topical PUVA treatment, and the other two were treated with mid-potency topical corticosteroids, resulting in complete clinical remission. A management approach to mycosis fungoides with topical PUVA may be appropriate for children.

2002 Journal of American Academy of Dermatology

1737. Mycosis fungoides: the great imitator. (PubMed)

Mycosis fungoides: the great imitator. A considerable number of reports have documented mycosis fungoides (MF) mimicking other dermatoses, but a comprehensive review has not been published. Our aim was to comprehensively review reports of various dermatoses simulated by MF. Additionally, 2 cases in which MF simulated diseases not previously documented (psoriasis and erythema annulare centrifugum) are presented. A literature search of all case reports of MF cited in the MEDLINE database from

2002 Journal of American Academy of Dermatology

1738. Clinicopathologic reassessment of non-mycosis fungoides primary cutaneous lymphomas during 17 years. (PubMed)

Clinicopathologic reassessment of non-mycosis fungoides primary cutaneous lymphomas during 17 years. New classification systems have recently been proposed for primary cutaneous lymphomas (PCLs). The aim of our study was to evaluate the applicability and significance of the new classification systems to the diagnosis and management of non-mycosis fungoides (non-MF) PCL.Immunohistochemical restaining, histological reclassification, and clinical follow-up of all new non-MF PCL cases during 17

2002 International Journal of Dermatology

1739. Cold urticaria in a patient with mycosis fungoides. (PubMed)

Cold urticaria in a patient with mycosis fungoides. We report what we believe to be the first documentation of a patient with both cold urticaria and mycosis fungoides. The patient described a marked worsening of his long-standing lesions of mycosis fungoides at the same time as the onset of cold sensitivity. We believe this suggests a possible association between these 2 rare diseases.

2002 Journal of American Academy of Dermatology

1740. Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. (PubMed)

Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome. Patients with cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] and Sézary syndrome [SS]) acquire immunodeficiency and opportunistic infections.We attempted to determine whether abnormalities of humoral immunoglobulin levels are present.A retrospective analysis of serum immunoglobulin levels in patients with CTCL at baseline evaluation at a cancer center was compared to levels in patients

2002 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>